The effect of Cryptococcus neoformans capsular GXM on energy metabolism and apoptosis of mouse microglia

Abstract

Abstract: Objective To detect the effect of Cryptococcus neoformans GXM on energy metabolism and apoptosis of mouse microglia cell.Method ①The capacity of ATP generation in each group was evaluated with UV spectrophotometric determination.②Annexin V-fluorescein isothiocyanate/propidium iodide double label Method was taken to detect apoptosis rate of BV-2 cells after co-incubation with GXM.Results ①The capacity of ATP generation decreased after intervention by GXM.②GXM was able to induce apoptosis in microglial cells in vitro.Conclusion Cryptococcus neoformans could exert effect on host cells via induction of energy metabolism disorder and apoptosis in microglia by GXM.

Key words: Cryptococcus neoformans, capsular polysaccharide, GXM, microglia, apoptosis

CLC Number:

R379.5

ZHOU Jie, PAN Wei-hua, LIAO Wan-qing. The effect of Cryptococcus neoformans capsular GXM on energy metabolism and apoptosis of mouse microglia[J]. Chinese Journal of Mycology, 2013, 8(5): 261-264.

References

[1] Zaragoza O, Rodrigues ML, De Jesus M, et al. The capsule of the fungal pathogen Cryptococcus neoformans[J]. Adv Appl Microbiol,2009,68:133-216.
[2] Buchanan KL, Murphy JW. What makes Cryptococcus neoformans a pathogen[J]? Emerg Infect Dis,1998,4(1):71-83.
[3] McClelland EE, Bernhardt P, Casadevall A. Estimating the relative contributions of virulence factors for pathogenic microbes[J]. Infect Immun, 2006,74(3):1500-1504.
[4] McFadden DC, De Jesus M, Casadevall A. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction[J]. J Biol Chem, 2006,281(4):1868-1875.
[5] Gates MA, Thorkildson P, Kozel TR. Molecular architecture of the Cryptococcus neoformans capsule[J]. Mol Microbiol,2004,52(1):13-24.
[6] O'Meara TR, Alspaugh JA. The Cryptococcus neoformans capsule: a sword and a shield[J]. Clin Microbiol Rev,2012,25(3):387-408.
[7] Grechi J, Marinho-Carvalho M, Zancan P,et al. Glucuronoxylomannan from Cryptococcus neoformans down-regulates the enzyme 6-phosphofructo-1-kinase of macrophages[J]. J Biol Chem,2011,286(17):14820-14829.
[8] Goldman DL, Casadevall A, Cho Y, et al. Cryptococcus neoformans meningitis in the rat[J]. Lab Invest,1996,75(6):759-770.
[9] Zhou Q, Gault RA, Kozel TR,et al. Protection from direct cerebral cryptococcus infection by interferon-gamma-dependent activation of microglial cells[J]. J Immunol, 2007, 178(9):5753-5761.
[10] Gupta AK. Types of onychomycosis[J]. Cutis,2001,68(2 Suppl):4-7.
[11] Wozniak KL, Levitz SM. Isolation and purification of antigenic components of Cryptococcus[J]. Methods Mol Biol,2009,470:71-83.
[12] Chiapello LS, Aoki MP, Rubinstein HR,et al. Apoptosis induction by glucuronoxylomannan of Cryptococcus neoformans[J]. Med Mycol, 2003,41(4):347-353.
[13] Kaur G, Han SJ, Yang I, et al. Microglia and central nervous system immunity[J]. Neurosurg Clin N Am, 2010,21(1):43-51.
[14] Retini C, Vecchiarelli A, Monari C, et al. Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes[J]. Infect Immun,1998,66(2):664-669.
[15] Vecchiarelli A, Pietrella D, Lupo P,et al. The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation[J]. J Leukoc Biol,2003,74(3):370-378.
[16] Cross CE, Bancroft GJ. Ingestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form[J]. Infect Immun,1995,63(7):2604-2611.
[17] Zaragoza O, Chrisman CJ, Castelli MV, et al. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival[J]. Cell Microbiol,2008,10(10):2043-2057.
[18] Syme RM, Bruno TF, Kozel TR,et al. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody[J]. Infect Immun, 1999,67(9):4620-4627.
[19] Dong ZM, Murphy JW. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation[J]. Infect Immun,1995,63(3):770-778.
[20] Vecchiarelli A, Retini C, Pietrella D, et al. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes[J]. Infect Immun,1995,63(8):2919-2923.
[21] Monari C, Paganelli F, Bistoni F, et al. Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms[J]. Cell Microbiol,2008,10(10):2129-2137.
[22] Monari C, Pericolini E, Bistoni G, et al. Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages[J]. J Immunol,2005,174(6):3461-3468.
[23] Villena SN, Pinheiro RO, Pinheiro CS, et al. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand[J]. Cell Microbiol,2008,10(6):1274-1285.
[24] Aubert M, Jerome KR. Apoptosis prevention as a mechanism of immune evasion[J]. Int Rev Immunol,2003,22(5-6):361-371.